{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-22-000030","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2022-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.407447+00:00","generated_at":"2026-06-23T00:40:24.737415+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioMarin Q3 revenue up 24% YoY to $505M; VOXZOGO guidance raised to $140-170M","bullets":["Total revenues $505.3M (+24% YoY); GAAP net loss narrowed to $6.7M from $36.5M; Non-GAAP income $82.7M.","VOXZOGO net product revenue $48.3M, with 713 children treated; full-year guidance raised to $140-170M.","ROCTAVIAN BLA accepted by FDA, PDUFA March 31, 2023; EU commercial launch underway after August 2022 approval.","KUVAN revenue fell 16% QoQ and 20% YTD due to U.S. generic competition, as expected.","Full-year total revenue guidance reaffirmed at $2.06-2.16B; R&D and SG&A guidance ranges revised modestly."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-22-000030","json":"https://secwatch.observer/filing/0001048477-22-000030.json","markdown":"https://secwatch.observer/filing/0001048477-22-000030.md","text":"https://secwatch.observer/filing/0001048477-22-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847722000030/0001048477-22-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847722000030/bmrn-20221026.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:40:24.737415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}